
Loss Narrowing Under Scrutiny—Can SPARC Sustain Momentum Without One-Offs?
SPARC · Q2 FY27 · loss narrowing
BSE: 532872
P/L Snapshot
Q2 FY27 · standalone
Shareholding
Pattern breakdown
P/L Trends
(in crores)

SPARC · Q2 FY27 · loss narrowing

pharma r&d · one-off revenue · licensing termination

SPARC · earnings preview · R&D biotech
Corporate Events
Board Meeting
The meeting of the Board of Directors is scheduled to consid…
BSE Filing ↗Board Meeting
The 21st Annual General Meeting ("AGM") of the Company will …
BSE Filing ↗Board Meeting
Consider and approve the Unaudited Standalone and Consolidat…
BSE Filing ↗Board Meeting
Consider and approve Unaudited Standalone and Consolidated F…
BSE Filing ↗Board Meeting
Consider and approve Audited Financial Statements for the ye…
BSE Filing ↗Board Meeting
Consider and approve Unaudited Standalone and Consolidated F…
BSE Filing ↗Board Meeting
Consider and approve audited financial results and propose r…
BSE Filing ↗